Virtual Library

Start Your Search

Jane Agar

Author of

  • +

    P1.16 - Treatment of Early Stage/Localized Disease (Not CME Accredited Session) (ID 948)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.16-12 - Identification of a Biomarker Panel in Resected NSCLC That Predicts Patient Outcomes and Benefit from Adjuvant Chemotherapy (ID 11789)

      16:45 - 18:00  |  Author(s): Jane Agar

      • Abstract
      • Slides


      Adjuvant chemotherapy for resected NSCLC improves overall survival by approximately 10%. Physicians need tools to predict which patients are most likely to benefit from chemotherapy, sparing those unlikely to benefit. A 15-gene expression profile (GEP) published by Zhu et al is both prognostic and predictive of benefit from adjuvant chemotherapy. The aim of this study is to translate this GEP into a readily applicable immunohistochemistry (IHC) panel.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      We constructed NSCLC tissue microarrays at the Saint John Regional Hospital and semiquantitatively assessed the IHC expression and prognostic significance of proteins encoded by 7 of the genes in the Zhu panel for which commercial antibodies were available.

      4c3880bb027f159e801041b1021e88e8 Result

      In 62 patients with resected stage II-III NSCLC, the prognostic significance of IHC assays for four proteins were concordant with the Zhu GEP results. Low FOSL2 (OS, HR = 2.6; p = 0.0231; PFS, HR = 3.3; p = 0.0052), and low ATP1B1 (PFS, HR = 2.0; p = 0.0338) were adverse prognostic factors. High STMN2 and low TRIM14 expression trended towards worse OS and PFS. Multivariate analysis verified the prognostic impact of the four assays. These markers could also be integrated as a panel with retained prognostic value (OS, HR=2.1, p=0.03).

      8eea62084ca7e541d918e823422bd82e Conclusion

      An IHC panel with results concordant to the Zhu GEP is prognostic. Ongoing studies will examine the prognostic and predictive impact of this IHC panel in larger, independent datasets. If the panel turns out to be robust and predictive, it will have potential clinical application as a tool to select patients for adjuvant chemotherapy.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.